{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:10:57Z","timestamp":1793661057353,"version":"4.5.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NCI Cancer Center Support Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}]},{"name":"NCI Cancer Center Support Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}]},{"name":"NCI Cancer Center Support Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}]},{"name":"NCI Cancer Center Support Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}]},{"name":"NCI Cancer Center Support Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}]},{"name":"NCI Cancer Center Support Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}]},{"name":"Repare Therapeutics"},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21\u20131-0282_OC200482"],"award-info":[{"award-number":["W81XWH-21\u20131-0282_OC200482"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2210504_BC211174"],"award-info":[{"award-number":["W81XWH2210504_BC211174"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA255074"],"award-info":[{"award-number":["1R01CA255074"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NCI Cancer Center Support","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-025-01025-1","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T19:16:00Z","timestamp":1751915760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanoma"],"prefix":"10.1038","volume":"9","author":[{"given":"Natalie Y. L.","family":"Ngoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenfeng","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Schonhoft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Ulanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Torrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Salguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Valladolid","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rodon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Rimkunas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"1025_CR1","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ccr.2007.02.026","volume":"11","author":"DM Feldser","year":"2007","unstructured":"Feldser, D. M. & Greider, C. W. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 11, 461\u2013469 (2007).","journal-title":"Cancer Cell"},{"key":"1025_CR2","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.tig.2017.09.003","volume":"33","author":"AP Sobinoff","year":"2017","unstructured":"Sobinoff, A. P. & Pickett, H. A. Alternative lengthening of telomeres: DNA repair pathways converge. Trends Genet. 33, 921\u2013932 (2017).","journal-title":"Trends Genet."},{"key":"1025_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21794-0","volume":"12","author":"A de Nonneville","year":"2021","unstructured":"de Nonneville, A. & Reddel, R. R. Alternative lengthening of telomeres is not synonymous with mutations in ATRX\/DAXX. Nat. Commun. 12, 1552 (2021).","journal-title":"Nat. Commun."},{"key":"1025_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1126\/science.1207313","volume":"333","author":"CM Heaphy","year":"2011","unstructured":"Heaphy, C. M. et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 333, 425 (2011).","journal-title":"Science"},{"key":"1025_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1126\/science.1257216","volume":"347","author":"RL Flynn","year":"2015","unstructured":"Flynn, R. L. et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 347, 273\u2013277 (2015).","journal-title":"Science"},{"key":"1025_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111081","volume":"40","author":"M Zimmermann","year":"2022","unstructured":"Zimmermann, M. et al. Guiding ATR and PARP inhibitor combinations with chemogenomic screens. Cell Rep. 40, 111081 (2022).","journal-title":"Cell Rep."},{"key":"1025_CR7","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap, T. A. et al. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat. Med. 29, 1400\u20131411 (2023).","journal-title":"Nat. Med."},{"key":"1025_CR8","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.1016\/j.jmb.2013.09.026","volume":"425","author":"M Tarsounas","year":"2013","unstructured":"Tarsounas, M. & Tijsterman, M. Genomes and G-quadruplexes: for better or for worse. J. Mol. Biol. 425, 4782\u20134789 (2013).","journal-title":"J. Mol. Biol."},{"key":"1025_CR9","doi-asserted-by":"publisher","first-page":"e1002772","DOI":"10.1371\/journal.pgen.1002772","volume":"8","author":"CA Lovejoy","year":"2012","unstructured":"Lovejoy, C. A. et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 8, e1002772 (2012).","journal-title":"PLoS Genet"},{"key":"1025_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s43556-021-00055-y","volume":"2","author":"E Claude","year":"2021","unstructured":"Claude, E. et al. Detection of alternative lengthening of telomeres mechanism on tumor sections. Mol. Biomed. 2, 32 (2021).","journal-title":"Mol. Biomed."},{"key":"1025_CR11","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1101\/gad.333963.119","volume":"34","author":"TK Loe","year":"2020","unstructured":"Loe, T. K. et al. Telomere length heterogeneity in ALT cells is maintained by PML-dependent localization of the BTR complex to telomeres. Genes Dev. 34, 650\u2013662 (2020).","journal-title":"Genes Dev."},{"key":"1025_CR12","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/nbt.1587","volume":"27","author":"JD Henson","year":"2009","unstructured":"Henson, J. D. et al. DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat. Biotechnol. 27, 1181\u20131185 (2009).","journal-title":"Nat. Biotechnol."},{"key":"1025_CR13","doi-asserted-by":"crossref","unstructured":"Chen, Y. Y., et al. The C-circle biomarker is secreted by alternative-lengthening-of-telomeres positive cancer cells inside exosomes and provides a blood-based diagnostic for ALT activity. Cancers 13, 5369 (2021).","DOI":"10.3390\/cancers13215369"},{"key":"1025_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ymeth.2016.08.016","volume":"114","author":"JD Henson","year":"2017","unstructured":"Henson, J. D. et al. The C-Circle Assay for alternative-lengthening-of-telomeres activity. Methods 114, 74\u201384 (2017).","journal-title":"Methods"},{"key":"1025_CR15","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.ajpath.2011.06.018","volume":"179","author":"CM Heaphy","year":"2011","unstructured":"Heaphy, C. M. et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am. J. Pathol. 179, 1608\u20131615 (2011).","journal-title":"Am. J. Pathol."},{"key":"1025_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-019-2851-0","volume":"20","author":"L Feuerbach","year":"2019","unstructured":"Feuerbach, L. et al. TelomereHunter\u2014n silico estimation of telomere content and composition from cancer genomes. BMC Bioinforma. 20, 272 (2019).","journal-title":"BMC Bioinforma."},{"key":"1025_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13824-9","volume":"11","author":"L Sieverling","year":"2020","unstructured":"Sieverling, L. et al. Genomic footprints of activated telomere maintenance mechanisms in cancer. Nat. Commun. 11, 733 (2020).","journal-title":"Nat. Commun."},{"key":"1025_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1158\/1535-7163.MCT-21-0615","volume":"21","author":"A Roulston","year":"2022","unstructured":"Roulston, A. et al. RP-3500: a novel, potent, and selective ATR inhibitor that is effective in preclinical models as a monotherapy and in combination with PARP inhibitors. Mol. Cancer Ther. 21, 245\u2013256 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"1025_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","volume":"21","author":"NYL Ngoi","year":"2024","unstructured":"Ngoi, N. Y. L. et al. Targeting ATR in patients with cancer. Nat. Rev. Clin. Oncol. 21, 278\u2013293 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1025_CR20","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/jnci\/djae098","volume":"116","author":"E Fontana","year":"2024","unstructured":"Fontana, E. et al. Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study). J. Natl. Cancer Inst. 116, 1439\u20131449 (2024).","journal-title":"J. Natl. Cancer Inst."},{"key":"1025_CR21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jmoldx.2023.02.004","volume":"25","author":"D Glodzik","year":"2023","unstructured":"Glodzik, D. et al. Detection of biallelic loss of DNA repair genes in formalin-fixed, paraffin-embedded tumor samples using a novel tumor-only sequencing panel. J. Mol. Diagn. 25, 295\u2013310 (2023).","journal-title":"J. Mol. Diagn."},{"key":"1025_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00497-x","volume":"8","author":"MS Pelster","year":"2024","unstructured":"Pelster, M. S. et al. Post-therapy emergence of an NBN reversion mutation in a patient with pancreatic acinar cell carcinoma. NPJ Precis Oncol. 8, 82 (2024).","journal-title":"NPJ Precis Oncol."},{"key":"1025_CR23","doi-asserted-by":"crossref","unstructured":"Islam, S. M. A., et al. Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor. Cell Genom. 2, (2022).","DOI":"10.1016\/j.xgen.2022.100179"},{"key":"1025_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19406-4","volume":"11","author":"L Nguyen","year":"2020","unstructured":"Nguyen, L., J, W. M. M., Van Hoeck, A. & Cuppen, E. Pan-cancer landscape of homologous recombination deficiency. Nat. Commun. 11, 5584 (2020).","journal-title":"Nat. Commun."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01025-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01025-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01025-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T19:16:01Z","timestamp":1751915761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01025-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1025"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-01025-1","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Natalie Ngoi has received advisory board honoraria from AstraZeneca, MSD, and Pfizer; and research funding (to Institution) from iOnctura SA. Ian M. Silverman, Adrienne Johnson, Chenfeng Meng, Joseph D. Schonhoft, Michal Zimmermann, Danielle Ulanet, Victoria Rimkunas, Hyeyeon Kim, and Maria Koehler are current or former employees of Repare Therapeutics and may hold stock and\/or stock options. Carlos Torrado, Carolina Salguero, and Christian Valladolid Brown have nothing to disclose. Jordi Rodon reports non-financial support and reasonable reimbursement for travel from European Society for Medical Oncology, American Society of Medical Oncology, National Taiwan University Cancer Center, 280-Biotech, Dava Oncology, STOP Cancer; receiving consulting and travel fees from Ellipses Pharma, IONCTURA, Sardona, Mekanistic, Amgen, Merus, MonteRosa, Aadi, and Bridgebio (including serving on the scientific advisory board); Consulting fees from Vall d\u2019Hebron Institute of Oncology, Chinese University of Hong Kong, Boxer Capital, LLC, Tang Advisors LLC, Guidepoint, and Axiom; research funding from Blueprint Medicines, Merck Sharp & Dohme, Hummingbird, AstraZeneca, 280 Bio, Vall d\u2019Hebron Institute of Oncology\/Cancer Core Europe; and serving as investigator in clinical trials with Cancer Core Europe, Symphogen, BioAlta, Pfizer, Kelun-Biotech, GlaxoSmithKline, Taiho, Roche Pharmaceuticals, Hummingbird, Yingli, Bicycle Therapeutics, Merus, AadiBioscience, ForeBio, Loxo Oncology, Hutchinson MediPharma, Ideaya, Amgen, Tango Therapeutics, Mirati, Linnaeus Therapeutics, MonteRosa, Kinnate, Debio, BioTheryX, Storm Therapeutics, Beigene, MapKure, Relay, Novartis, FusionPharma, C4 Therapeutics, Scorpion Therapeutics, Incyte, Fog Pharmaceuticals, Tyra, Nuvectis Pharma, Hotspot Pharma, Adcentrix, Vividion, AstraZeneca, Alnylam, Immuneering Corp, Alterome, and Exelixis. Timothy A. Yap is an employee of The University of Texas MD Anderson Cancer Center, where he is Vice President, Head of Clinical Development in the Therapeutics Discovery Division, which has a commercial interest in DDR and other inhibitors (IACS30380\/ART0380 was licensed to Artios); has received funding paid to their institution from Acrivon, Artios, AstraZeneca, Bayer, BeiGene, BioNTech, Blueprint, Bristol Myers Squibb, Boundless Bio, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GlaxoSmithKline, Genentech, Haihe, Ideaya ImmuneSensor, Insilico Medicine, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Mirati, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Rubius, Sanofi, Scholar Rock, Seattle Genetics, Tango, Tesaro, Vivace, and Zenith; has received consultancy funding from AbbVie, Acrivon, Adagene, Almac, Aduro, Amphista, Artios, Astex, AstraZeneca, Athena, Atrin, Avenzo, Avoro, Axiom, Baptist Health Systems, Bayer, BeiGene, BioCity Pharma, Blueprint, Boxer, Bristol Myers Squibb, C4 Therapeutics, Calithera, Cancer Research UK, Carrick Therapeutics, Circle Pharma, Clovis, Cybrexa, Daiichi Sankyo, Dark Blue Therapeutics, Diffusion, Duke Street Bio, 858 Therapeutics, EcoR1 Capital, Ellipses Pharma, EMD Serono, Entos, F-Star, Genesis Therapeutics, Genmab, Glenmark, GLG, Globe Life Sciences, GSK, Guidepoint, Ideaya Biosciences, Idience, Ignyta, I-Mab, ImmuneSensor, Impact Therapeutics, Institut Gustave Roussy, Intellisphere, Jansen, Kyn, MEI pharma, Mereo, Merck, Merit, Monte Rosa Therapeutics, Natera, Nested Therapeutics, Nexys, Nimbus, Novocure, Odyssey, OHSU, OncoSec, Ono Pharma, Onxeo, PanAngium Therapeutics, Pegascy, PER, Pfizer, Piper-Sandler, Pliant Therapeutics, Prolynx, Radiopharma Theranostics, Repare, resTORbio, Roche, Ryvu Therapeutics, SAKK, Sanofi, Schrodinger, Servier, Synnovation, Synthis Therapeutics, Tango, TCG Crossover, TD2, Terremoto Biosciences, Tessellate Bio, Theragnostics, Terns Pharmaceuticals, Tolremo, Tome, Thryv Therapeutics, Trevarx Biomedical, Varian, Veeva, Versant, Vibliome, Voronoi Inc, Xinthera, Zai Labs, and ZielBio; and is a stockholder in Seagen. He was supported by the NCI Cancer Center Support Grant CA016672 to The University of Texas MD Anderson Cancer Center, Department of Defense grants W81XWH2210504_BC211174 and W81XWH-21-1-0282_OC200482, V Foundation Scholar Grant VC2020-001, and NIH R01 grant 1R01CA255074.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"227"}}